Decrypt Biomedicine develops small-molecule drugs that target cryptic binding sites on proteins to treat cancer and autoimmune diseases. By focusing on these hidden sites, the company aims to enhance therapeutic efficacy and reduce side effects associated with conventional treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for cancer and autoimmune diseases often have limited efficacy and significant side effects due to their broad targeting mechanisms. Many proteins possess cryptic binding sites that are not targeted by conventional drugs, potentially offering a more selective therapeutic approach.
Solution
Decrypt Biomedicine is developing small-molecule drugs that selectively target cryptic binding sites on proteins implicated in cancer and autoimmune diseases. By focusing on these previously unexploited sites, the company aims to create therapeutics with enhanced efficacy and reduced off-target effects compared to traditional treatments. Their approach involves identifying and characterizing these cryptic binding pockets, then designing small molecules that specifically bind to and modulate the activity of the target protein. This targeted approach has the potential to improve patient outcomes by minimizing systemic toxicity and maximizing therapeutic impact.
Target Audience
The primary target audience includes patients suffering from cancer and autoimmune diseases, as well as pharmaceutical companies seeking novel therapeutic candidates with improved safety profiles.
Features
- Focus on small-molecule drug development
- Target cryptic binding sites on proteins
- Therapeutic focus on cancer and autoimmune diseases
- Aims to enhance therapeutic efficacy
- Aims to reduce side effects